Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu, Lin Shen, Zhiwei Zhou, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 11, pp. 1500-1512
Closed Access | Times Cited: 149

Showing 1-25 of 149 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1127
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Sonia Patel, Monique B. Nilsson, Xiuning Le, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 1, pp. 30-39
Open Access | Times Cited: 205
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Seyedehdelaram Ghalehbandi, Jale Yüzügülen, Md Zahidul Islam Pranjol, et al.
European Journal of Pharmacology (2023) Vol. 949, pp. 175586-175586
Open Access | Times Cited: 129
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment
Jiachen Wen, Siyuan Wang, Rongxian Guo, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114884-114884
Closed Access | Times Cited: 78
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours
Anja Rinke, Valentina Ambrosini, Clarisse Dromain, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 6
Open Access | Times Cited: 64
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 48
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
Jennifer A. Chan, Susan M. Geyer, Tyler Zemla, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 16
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu, Lin Shen, Chunmei Bai, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 11, pp. 1489-1499
Closed Access | Times Cited: 134
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos López, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 20, pp. 2304-2312
Open Access | Times Cited: 78
Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases
Caigui Xiang, Heng Li, Wei Tang
Pharmacological Research (2022) Vol. 187, pp. 106566-106566
Open Access | Times Cited: 49
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
James C. Yao, Emily K. Bergsland, Rahul Aggarwal, et al.
The Oncologist (2022) Vol. 27, Iss. 11, pp. 940-951
Open Access | Times Cited: 43
Small-molecule agents for cancer immunotherapy
Fang Wang, Kai Fu, Yujue Wang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 3, pp. 905-952
Open Access | Times Cited: 22
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Gastric neuroendocrine neoplasms
Giuseppe Lamberti, Francesco Panzuto, Marianne Pavel, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 12
European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well‐differentiated small intestine neuroendocrine tumours
Ángela Lamarca, Detlef K. Bartsch, Martyn Caplin, et al.
Journal of Neuroendocrinology (2024) Vol. 36, Iss. 9
Open Access | Times Cited: 11
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
Panpan Zhang, Si Shi, Jianming Xu, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113539-113539
Open Access | Times Cited: 9
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives
Xianbin Zhang, Yibao Fan, Rui Jing, et al.
Military Medical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 9
Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets
Chandra K. Maharjan, Po Hien Ear, Catherine G. Tran, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5117-5117
Open Access | Times Cited: 51
Integrated proteogenomic characterization of medullary thyroid carcinoma
Xiao Shi, Yaoting Sun, Cenkai Shen, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 37
Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotyczących postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]
Beata Kos‐Kudła, Wanda Fołtyn, Anna Malczewska, et al.
Endokrynologia Polska (2022) Vol. 73, Iss. 3, pp. 387-454
Open Access | Times Cited: 35
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
Taymeyah Al‐Toubah, Michael J. Schell, Brian Morse, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102386-102386
Open Access | Times Cited: 6
Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
Thomas A. Hope, Marianne Pavel, Emily K. Bergsland
Journal of Clinical Oncology (2022) Vol. 40, Iss. 24, pp. 2818-2829
Open Access | Times Cited: 26
Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines
Amr Mohamed, Sulin Wu, Mohamed E. Hamid, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 295-295
Open Access | Times Cited: 26
Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States
Rongshou Zheng, Hong Zhao, Lan An, et al.
Chinese Medical Journal (2023)
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top